WO2006126035A2 - Process for the preparation of rosuvastatin - Google Patents

Process for the preparation of rosuvastatin Download PDF

Info

Publication number
WO2006126035A2
WO2006126035A2 PCT/HU2006/000049 HU2006000049W WO2006126035A2 WO 2006126035 A2 WO2006126035 A2 WO 2006126035A2 HU 2006000049 W HU2006000049 W HU 2006000049W WO 2006126035 A2 WO2006126035 A2 WO 2006126035A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
salt
compound
reacting
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2006/000049
Other languages
French (fr)
Other versions
WO2006126035A3 (en
Inventor
János Fischer
Attila SZEMZÖ
Krisztina Vukics
Péter ERDÉLYI
Katalin SZÖKE
Andrea DONÁT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Vegyeszeti Gyar Nyrt
Original Assignee
Richter Gedeon Vegyeszeti Gyar RT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszeti Gyar RT filed Critical Richter Gedeon Vegyeszeti Gyar RT
Priority to MEP-2010-158A priority Critical patent/ME01781B/en
Priority to HR20100290T priority patent/HRP20100290T1/en
Priority to PL06744403T priority patent/PL1902036T3/en
Priority to RSP-2010/0158A priority patent/RS51205B/en
Priority to DK06744403.4T priority patent/DK1902036T3/en
Priority to AT06744403T priority patent/ATE461924T1/en
Priority to EP06744403A priority patent/EP1902036B1/en
Priority to DE602006013136T priority patent/DE602006013136D1/en
Priority to EA200702579A priority patent/EA013304B1/en
Publication of WO2006126035A2 publication Critical patent/WO2006126035A2/en
Publication of WO2006126035A3 publication Critical patent/WO2006126035A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to a new process for the preparation of a HMG-CoA reductase inhibitor rosuvastatin of formula I
  • the further subject of the present invention is a compound of formula III and its salts formed by organic and inorganic base.
  • Rosuvastatin (chemical name: (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- (methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-anoic acid calcium salt) and its preparation process is described in European Patent EP 521471.
  • the active ingredient is prepared by the reduction of 7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino] ⁇ yrimidin-5-yl](3R)-3-hydroxy-5-oxo-(E)-heptenoic acid and further steps of preparation. It is not a cost-effective preparation process because the 5S- hydroxy group of the side chain forming heptanoic acid is synthesized at the and of the preparation process, in one of the last steps.
  • the sodium salt of the end product is prepared from BEM by the cleavage of the acetonide protecting group by acid hydrolysis using 0,02 M hydrochloric acid at 40 °C and by the cleavage of the tert-butyl protecting group using 1 M sodium hydroxide at 25 0 C.
  • the carboxylic acid is liberated from the sodium salt of rosuvastatin with hydrochloric acid (1 M) at -5 °C at a pH between 3. 4 and 4. 0.
  • the methylamine salt is isolated from carboxylic acid with 40 % methylamine solution in water with a yield of 82 %.
  • the methylamine salt is converted again to sodium salt with 8 % w/w aqueous sodium hydroxide solution and the methyl amine is eliminated with a complicated distillation process.
  • the end product is prepared from the sodium salt by calcium chloride dihydrate. The application does not contain any data about the yield of the end product.
  • Salts of the new compound of formula III can be prepared with high purity and a yield of 90 %. Salts formed from the compound of formula III with an organic or inorganic base can be prepared by a good yield an it can be easily purified. The crystalline nature of these salts ensures a pure end product, which is acknowledged as an important active ingredient in the pharmaceutical industry.
  • the following bases can be used advantageously for the salt formation: methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine,
  • salts are diethanolamine, L-lysine and magnesium salts. These bases are known salt-forming agents at the salt formation of other active ingredients, as well. (P.H.Stahl, C.G.Wermuth (Eds.) Handbook of Pharmaceutical Salts; Properties, Selection and Use, Wiley-VCH, 2002).
  • the subject of the present invention is a process for the preparation of rosuvastatin of formula I
  • the neutral organic solvent is preferably acetonitrile, ethyl-acetate or ethanol.
  • the salt formation is carried out preferably with diethanolamine, L-lysine or magnesium sulfate.
  • a further subject of the present invention is a compound of formula III
  • a further subject of our invention is a salt of a compound of formula III formed by methylarnine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-
  • Alkylesters of general formula II was prepared according to the process described in
  • the preparation of an acid of formula III can be carried out by the alkalic hydrolysis of alkylesters of formula II advantageously in tetrahydrofuran with IM sodium hydroxide.
  • a new salt is formed from the compound of formula III with organic or inorganic base in hydrous or anhydrous, neutral solvent.
  • the salt formation is carried out preferably with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine,
  • Salts formed from the a compound of formula III can be used for the preparation of calcium-E-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihidroxihept-6-enoic acid.
  • Acetonide protecting group was cleaved by heating of the above mentioned salts with 1 M hydrochloric acid solution at 80 0 C and the filterable amorphous solid product can be prepared from a salt -formed with a strong base, preferably with alkali hydroxide- with calcium-chloride solution. After filtering and drying 90 % yield of the active ingredient was obtained.
  • the main aspect of the present invention is the preparation of rosuvastatin preparing a new carboxylic acid of formula III from the alkyl ester of formula II and purifying by its salts, which were formed with organic or inorganic base.
  • HMG-CoA reductase inhibitor rosuvastatin can be prepared from these salts with a yield of 90%.
  • the advantage of the preparation process of the present invention contrary to the preparation process described in the International Patent Application WO 00/49014 is that methylamine salt is not used. Consequently the difficult elimination of methylamine by distillation has not to bee carried out.
  • a further advantage is that the salt prepared from the base used for the salt formation does not contaminate the end product, because the acetonide protecting group is eliminated at the last step by hydrochloric acid (1 M) and the base is located in the aqueous phase as a hydrochloride salt.
  • This preparation does not increases the number of steps of the process, in the contrary, it makes the process simpler because the base is eliminated by simple salt formation instead of distillation.
  • the new salts prepared according to the invention can be purified easily. Contrary to the process described in International Patent Application WO 2004/108691, wherein the purification of the amorphous end product can not be carried out, our process ensures the preparation of pure calcium-E-7-[4-(4-fiuorphenyl)-6-isopropyl-2-
  • reaction mixture was stirred at -75 °C for 1 hour and the resulted suspension was warmed up to -20 °C over 1 hour.
  • the residue was solved in ethanol (30 ml) and the product was crystallized at +4 °C. The crystals were filtered and washed in cold ethanol (20 ml) and dried. Yield: 4.7 g (60%). Melting point: 191-3 0 C.
  • the reaction mixture was diluted with ethyl-acetate (50 ml), the aqueous phase was separated and the organic phase was extracted with water (20 ml) then the organic phase was concentrated in vacuum. Water (100 ml) was added to the residue and the solution was treated with 1 M hydrogen chloride solution by cooling with ice-cold water. The precipitated product was filtered off, washed with cold water (2x 50 ml) and dried at 50 0 C.
  • the reaction mixture was cooled to room temperature and ethyl acetate was added to the solution, then by stirring sodium hydroxide solution (2 M, 15 ml, 30 mmol) was added to the reaction mixture.
  • the organic and aqueous phase was separated and the organic phase was extracted with brine (2x20 ml), and concentrated.
  • the residue was dissolved in water (40 ml) and by stirring and cooling with ice-cool water an aqueous solution of calcium-chloride (1.62 g,ll mmol) in 20 ml water was added dropwise to the solution.
  • the reaction mixture was stirred for 1 hour by cooling then it was stirred for 10-15 hours at room temperature.
  • the precipitated product was filtered off and washed with ice-cool water (3x20 ml).
  • the title product was dried in vacuum at 40 0 C. Yield: 4.5 g (90%). Melting point: 150-180 °C, protracted.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The subject of the present invention is a process for the preparation of rosuvastatin by reacting a compound of formula II, by alkalic hydrolysis to give a compound of formula III, thereafter reacting with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base. A further subject of the present invention is a compound of formula III and its salts formed by organic or inorganic base.

Description

A
Process for the preparation of rosuvastatin by new intermediates
The present invention relates to a new process for the preparation of a HMG-CoA reductase inhibitor rosuvastatin of formula I
Figure imgf000003_0001
which comprises one of the following processes a.) reacting a compound of formula II
Figure imgf000003_0002
-wherein R represents C1-4 alkyl except tert-butyl group- by alkalic hydrolysis to give a compound of formula III
Figure imgf000004_0001
thereafter reacting with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or b.) reacting a compound of formula III
Figure imgf000004_0002
with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or c.) reacting a salt of a compound of formula III
Figure imgf000004_0003
-formed with an organic or inorganic base- by eliminating the acetonide group and reacting with calcium-chloride in a base.
The further subject of the present invention is a compound of formula III and its salts formed by organic and inorganic base.
Rosuvastatin (chemical name: (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- (methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-anoic acid calcium salt) and its preparation process is described in European Patent EP 521471. The active ingredient is prepared by the reduction of 7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]ρyrimidin-5-yl](3R)-3-hydroxy-5-oxo-(E)-heptenoic acid and further steps of preparation. It is not a cost-effective preparation process because the 5S- hydroxy group of the side chain forming heptanoic acid is synthesized at the and of the preparation process, in one of the last steps.
Another preparation process of rosuvastatin is described in International Patent Application WO 00/49014. According to this process tert-butyl-E-(6-{2-[4-(4-fluorophenyl)- 6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-vinyl}-((4R,6S)-2,2- dimethyl[l,3]dioxan-4-yl) acetic acid which is a key intermediate and abbreviated as BEM, is prepared by the reaction of diphenyl-[4-(4-fluorphenyl)-6-isopropyl-2-
[methyl(methylsulfonyl)amino]pyrimidin-5-ylmethyl]phosphine oxide and tert-butyl-2- [(4R,6S)-6-formyl-2,2-dimethyl-l,3-dioxan-4-yl] acetic acid.
According to the WO 00/49014 PCT-application the sodium salt of the end product is prepared from BEM by the cleavage of the acetonide protecting group by acid hydrolysis using 0,02 M hydrochloric acid at 40 °C and by the cleavage of the tert-butyl protecting group using 1 M sodium hydroxide at 25 0C. The carboxylic acid is liberated from the sodium salt of rosuvastatin with hydrochloric acid (1 M) at -5 °C at a pH between 3. 4 and 4. 0. The methylamine salt is isolated from carboxylic acid with 40 % methylamine solution in water with a yield of 82 %. The methylamine salt is converted again to sodium salt with 8 % w/w aqueous sodium hydroxide solution and the methyl amine is eliminated with a complicated distillation process. The end product is prepared from the sodium salt by calcium chloride dihydrate. The application does not contain any data about the yield of the end product.
International Patent Application WO 00/49014 describes a long, complicated preparation process containing six-operational steps for the preparation of the pharmaceutical drug. The disadvantage of the above mentioned process is the use of methylamine, which is unhealthy. The basic character and the volatility of methylamine induce its toxic, mucosa- destroying, mutagen and teratogen effects. (MSDS Data Sheet: http://physchem.ox.ac.uk/MSDS/; NCI Chem Carcinogenesis Res Info System: http://toxnet.nlm.nih.gov/ ; Schardein JL Chemically Induced Birth Defects 1993;2:842-69 ). The last part of the preparation -before the separation of the calcium salt- does not contain any possibility for the ideal purification. The first obtained sodium salt can not be purified and the methylamine salt prepared from the carboxylic acid can contaminate the product, because its elimination by distillation is difficult.
The above mentioned disadvantages result the low yields, altogether 60-70 % of the preparation process described in WO 00/49014.
International Patent Application WO 2004/108691 relate to an alternative solution for the preparation of rosuvastatin using the BEM intermediate. The end product is obtained from the ester without the preparation of a salt of the intermediate. The difference compared to the preparation process described in WO 00/49014 PCT-application is that the purification step with methylamine salt is missing and E-7-[4-(4-fluorphenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-diliydroxyhept-6-enoate salt is prepared directly from the sodium salt, obtained by ester hydrolysis. The sodium salt obtained by this process can not be purified.
Considering to the above mentioned disadvantages our aim was to work out a new, simple process for preparing crystalline intermediates of high purity which enables to prepare rosuvastatin with a high purity and with significantly improved yields.
During our experiments a new compound of formula III
Figure imgf000007_0001
and its salts formed by organic or inorganic base was prepared.
Salts of the new compound of formula III can be prepared with high purity and a yield of 90 %. Salts formed from the compound of formula III with an organic or inorganic base can be prepared by a good yield an it can be easily purified. The crystalline nature of these salts ensures a pure end product, which is acknowledged as an important active ingredient in the pharmaceutical industry. The following bases can be used advantageously for the salt formation: methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine,
benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine. Especially preferred
salts are diethanolamine, L-lysine and magnesium salts. These bases are known salt-forming agents at the salt formation of other active ingredients, as well. (P.H.Stahl, C.G.Wermuth (Eds.) Handbook of Pharmaceutical Salts; Properties, Selection and Use, Wiley-VCH, 2002). The subject of the present invention is a process for the preparation of rosuvastatin of formula I
Figure imgf000008_0001
which comprises one of the following processes b.) reacting a compound of formula II,
Figure imgf000008_0002
-wherein R represents C1-4 alkyl except tert-butyl group- by alkalic hydrolysis to give a compound of formula III
Figure imgf000009_0001
thereafter reacting with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or b.) reacting a compound of formula III
Figure imgf000009_0002
with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or c.) reacting a salt of a compound of formula III
Figure imgf000009_0003
-formed with an organic or inorganic base- by eliminating the acetonide group and reacting with calcium-chloride in a base.
In the preparation of compound of formula I the salt formation is carried out in a hydrous or anhydrous, neutral organic solvent.
In the preparation of compound of formula I the neutral organic solvent is preferably acetonitrile, ethyl-acetate or ethanol.
In the preparation of compound of formula I the salt formation from compound of formula III is carried out with methylamine, diethanolamine, ethanolamine, magnesium
sulfate, L-lysine, benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine.
In the preparation of compound of formula I the salt formation is carried out preferably with diethanolamine, L-lysine or magnesium sulfate.
In the preparation of compound of formula I the elimination of the acetonide group is carried out in neutral solvent in the presence of an acid.
In the preparation of compound of formula I the neutral solvent is tetrahydrofuran.
A further subject of the present invention is a compound of formula III
Figure imgf000010_0001
and its salts formed by organic or inorganic base. A further subject of our invention is a salt of a compound of formula III formed by methylarnine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-
α-methyl-benzylamine or N-methyl-D-glucosamine.
Other subjects of our invention are (6-{(E)-2-[4-(4-fluorophenyl)-6~isopropyl-2- (methanesulfonyl-methyl-amino)-6-methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl- [l,3]dioxan-4-yl)-acetic acid-diethanolamine salt, (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl- 2-(methanesulfonyl-methylamme)-6-methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl- [l,3]dioxan-4-yl)-acetic acid-L-lysine salt and (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2- (methanesulfonyl-methylamine)-6-methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl- [l,3]dioxan-4-yl)-acetic acid-magnesium salt.
Alkylesters of general formula II was prepared according to the process described in
International Patent Application WO 00/49014 by the reaction of N-[5-[(
diphenylphosphinoil)-methyl]-4-(4-fluorophenyl)-6-isopropyl-pyrimidin-2-yl]-N-methyl-
methansulfonamide and 6-formyl-2,2-dimethyl-l,3-dioxan-4-yl-acetic acid in the presence of a strong base.
The preparation of an acid of formula III can be carried out by the alkalic hydrolysis of alkylesters of formula II advantageously in tetrahydrofuran with IM sodium hydroxide.
Thereafter a new salt is formed from the compound of formula III with organic or inorganic base in hydrous or anhydrous, neutral solvent. The salt formation is carried out preferably with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine,
benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine.
Salts formed from the a compound of formula III can be used for the preparation of calcium-E-7-[4-(4-fluorphenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5- yl](3R,5S)-3,5-dihidroxihept-6-enoic acid. Acetonide protecting group was cleaved by heating of the above mentioned salts with 1 M hydrochloric acid solution at 80 0C and the filterable amorphous solid product can be prepared from a salt -formed with a strong base, preferably with alkali hydroxide- with calcium-chloride solution. After filtering and drying 90 % yield of the active ingredient was obtained.
The main aspect of the present invention is the preparation of rosuvastatin preparing a new carboxylic acid of formula III from the alkyl ester of formula II and purifying by its salts, which were formed with organic or inorganic base. HMG-CoA reductase inhibitor rosuvastatin can be prepared from these salts with a yield of 90%. The advantage of the preparation process of the present invention contrary to the preparation process described in the International Patent Application WO 00/49014 is that methylamine salt is not used. Consequently the difficult elimination of methylamine by distillation has not to bee carried out. A further advantage is that the salt prepared from the base used for the salt formation does not contaminate the end product, because the acetonide protecting group is eliminated at the last step by hydrochloric acid (1 M) and the base is located in the aqueous phase as a hydrochloride salt. This preparation does not increases the number of steps of the process, in the contrary, it makes the process simpler because the base is eliminated by simple salt formation instead of distillation.
The new salts prepared according to the invention can be purified easily. Contrary to the process described in International Patent Application WO 2004/108691, wherein the purification of the amorphous end product can not be carried out, our process ensures the preparation of pure calcium-E-7-[4-(4-fiuorphenyl)-6-isopropyl-2-
[memyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihidroxihept-6-enoic acid. Examples
Example 1
C6-/CE)—2-F4-C4-fluorophenyl)-6-isopropyl-2-methanesulfonyl-methyl-amino) — 6-methyl-
pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethvUl,31dioxan-4-yl)-acetic acid- ethylester
N-[5-[(diphenylphosphinoyl)-methyl]-4-(4-fluorophenyl)-6-isopropyl-pyriinidin-2-
yl]-N-methyl-methanesulfonamide (6.4 g, 14.3 mmol) was dissolved in anhydrous
tetrahydroforan (105 ml) in a flask dried in vacuum at 120 0C in argon atmosphere and 3 g molecular sieve (Merck, 3 A) was added to the solution and it was cooled to -75-78 0C in the mixture of acetone and solid carbone dioxide. Sodium-bis-trimethylsilyl-amide (21.2 ml, 21.1 mmol, 1.0 M/THF) was added dropwise to the reaction mixture over 20 minutes. It was stirred and kept at the same temperature for 10 minutes then 6-formil-2,2-dimethyl-l,3- dioxan-4-yl-acetic acid-ethylester (4.1 g, 18 mmol) in toluol (83 ml) was added to the mixture over 20 minutes.
The reaction mixture was stirred at -75 °C for 1 hour and the resulted suspension was warmed up to -20 °C over 1 hour. The reaction mixture was added to water (50 ml) in extraction runnel and the flask was washed with toluol-THF mixture (50 ml, ratio= 1:1) and water then it was extracted twice with brine (2 x 50 ml). The residue was solved in ethanol (30 ml) and the product was crystallized at +4 °C. The crystals were filtered and washed in cold ethanol (20 ml) and dried. Yield: 4.7 g (60%). Melting point: 191-3 0C. (6-{(E)-2-[4-(4-fluowphenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl- pyrimidin-5-yl] -vinyl}-(4R, 6S)-2,2-dimethyl-[l, 3] dioxan-4-yl)-acetic acid-methylester was prepared according to the method described above in example 1 with the difference that after adding dropwise sodium-bis-trimethylsilil-amide to the parent material 6~formil-2,2-dimethyl- l,3-dioxan-4-yl-acetic acid-methylester was added to the solution. Yield: 4.8 g (63 %) Melting point: 130-132 °C
Example 2 (6-{(E)-2-f4-(4-fluorophenyl)-64sopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl- pyrimidin-5-yl] -yinyl}-(4R, 6S)-2, 2-dimethyl-fl, 3] 'dioxan-4-yϊ) -acetic acid
(6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6- methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l ,3]dioxane-4-yl)-acetic acid ethylester
(5.52g, 10 mmol) was dissolved in tetrahydrofuran (10 ml) and IM sodium hydroxide 30 ml, 30 mmol) was added to the solution by stirring and it was heated to 90-100 0C. The reaction mixture was kept at this temperature until the parent material is transformed (ca. 4-6 hours).
(It was analyzed by thin layer chromatography on silica gel in toluol-ethyl acetate (6:1)).
The reaction mixture was diluted with ethyl-acetate (50 ml), the aqueous phase was separated and the organic phase was extracted with water (20 ml) then the organic phase was concentrated in vacuum. Water (100 ml) was added to the residue and the solution was treated with 1 M hydrogen chloride solution by cooling with ice-cold water. The precipitated product was filtered off, washed with cold water (2x 50 ml) and dried at 50 0C.
Yield: 4.9 g (95%)
Melting point: 172-174 °C Example 3
(6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl- pyrimidin-5-yll -vinyl}-(4R, 6S)-2,2-dimethyl-[l ,3] dioxan-4-yl)-acetic acid -methylamine salt (6-{(E)-2-[4-(4-fluorphenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6- metliyl-pyriniidm-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) prepared according to the method described in example 2 was dissolved in acetonitrile and methylamine (1.7 ml, 25 mmol) in 1 M ethanol was added to the solution and it was heated to 80-90 °C and kept at this temperature for 30 minutes. Then the reaction mixture was stirred at room temperature for 10-16 hours and the product was filtered and washed with cold acetonitrile (30 ml) and dried. Yield: 4.7 g (85%). Melting point: 190-192 °C.
Example 4
(6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl- pyrimidin-5-yl] '-vinyl}-(4R,6S)-2,2-dimethyl-[l ,3) ' dioxan-4-yl) -acetic acid-diethanolamine salt
(6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6- memyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid- was prepared according to the method described in example 2.
To the solution of (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl- methyl-ammo)-6-memyl-pvrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)- acetic acid (4.9 g, 9.4 mmol) with ethyl-acetate diethanolamine (1.6 ml, 17 mmol) was added dropwise at 80 0C. The reaction mixture was stirred for 10-16 hours at room temperature, and the precipitate was filtered, washed with cold ethyl acetate (30 ml) and dried at room temperature. Yield: 4.7 g (75%). Melting point: 151-3 °C.
Example 5
(6-{(E)-2-[4-(4-fluorophenyl}-64sopropyl-2-(methanesulfonyl-methyl-amino)-6-tnethyl- pyrimidin-5-yl] ' -vinyl}-(4R, 6S)-2,2-dimethyl-[l ,3] ' dioxan-4-yl)-acetic acid -ethanolamin salt A (6- {(E)-2-[4-(4-fluorophenyl)-6-isoρropyl-2-(methanesulfonyl-methyl-amino)-6- methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid- was prepared according to the method described in example 2.
A solution of (6- {(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl- amino)-6-methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) and acetonitrile (110 ml) was heated to 70 °C and 1,1 equivalent ethanolamine was added dropwise to the solution then it was cooled to 50 0C and kept at this temperature for 120 minutes. The reaction mixture was cooled to room temperature over 2 hours and the mixture was cooled in ice-cool water for another 2 hours, filtered and washed with cold acetonitrile (30 ml). The product was dried in vacuum at 40 °C. Yield: 4.9 g (85%).
Melting point: 151 - 153 °C. Example 6
C6-{fE)-2-f4-C4-fluorophenyl)-6-isopropyl-2-fmethanesulfonyl-methyl-amino)-6~methyl- yyrimidin-5-yl] '-vinyl}-('4R,6S)-2,2-dimethyl-fl ,3] 'dioxon-4-yl) -acetic acid)-masnesium salt
A (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6- methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid was prepared according to the method described in example 2.
A solution of (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl- amino)-6-methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) and acetonitrile was concentrated and the residue was dissolved in water (80 ml). Sodium hydroxide (10 ml, 1 M) was added to the solution and a solution of magnesium sulfate dehydrate (1,4 g, 12 mmol) in water (5 ml) was added dropwise to the reaction mixture. It was stirred for 10-16 hours at room temperature, filtered, washed twice with icy water (2x30 ml) and dried. Yield: 4.8 g (90%). Melting point: 175-182 °C.
Example 7
(6-{(E)-2-[4-(4-βuorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl- pyrimidin-5-yll -vinyl}-(4R, 6S)-2, 2-dimethyl-Fl,31 dioxan-4-yl) -acetic acid-L-lysine salt (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6- methyl-pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l ,3]dioxan-4-yl)-acetic acid was prepared according to the method described in example 2.
A solution of (6- {(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl- amino)-6-methyl-pyrimidin-5-yl]-Λdnyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid (4.9 g, 9.4 mmol) in 80 % ethanol- water 1,1 equivalent L-lysine was added dropwise and the product was filtered, washed with ethanol and dried.
Yield: 4.0 g (60%).
Melting point: 205-208 °C.
Examples 8-10
The following salt were prepared according to the method described in examples 3-7.
(6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl- pyrimidin-5-yl]-vinyl}-(4R, 6S)-2, 2-dimethyl-[l, 3] dioxan-4-yl)-acetic acid -benzylamine salt Yield: 89%;
Melting point: 171-173 °C
(6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl-
pyrimidin-5-yl] -vinyl}-(4R,6S)-2,2-dimethyl-[l,3] dioxan-4-yl)-acetic acid -L(-)-a-methyl-
benzylamine salt Yield: 84% ;
Melting point: 200-202 °C
(6-{(E)-2-[4-(4φuorophenyl)-64sopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl- pyrimidin-5-yl]-vinyl}-(4R, 6S)-2, 2-dimethyl-[l, 3]dioxan-4-yl)-acetic acid -N-methyl-D- glucosamine salt Yield: 75% ;
Melting point: 170-172 °C Example 11
Amorphous (E)-7-f4-(4-fluorophenyl)-6-isopr-opyl-2-(methanesulfonyl-methyl-amino)- pyrimidin-5-yl] -3 ,5-dihiώ'oxi-hept-6-anoic acid calcium salt (rosuvastatin-Ca)
(6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-aniino)-6-methyl- pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid -methylamine salt (5.52g, 10 mmol) prepared according to the method described in example 3 was suspended in tetrahydrofuran (150 ml) and by stirring hydrochloric acid (1 M, 20 ml, 20 mmol) was added to the suspension and the mixture was heated to 80 0C. Heating was carried out until the parent material was totally transformed (20-30 minutes). (It was analyzed by thin layer chromatography on silica gel in chloroform-methanol (10:1)).
The reaction mixture was cooled to room temperature and ethyl acetate was added to the solution, then by stirring sodium hydroxide solution (2 M, 15 ml, 30 mmol) was added to the reaction mixture. The organic and aqueous phase was separated and the organic phase was extracted with brine (2x20 ml), and concentrated. The residue was dissolved in water (40 ml) and by stirring and cooling with ice-cool water an aqueous solution of calcium-chloride (1.62 g,ll mmol) in 20 ml water was added dropwise to the solution. The reaction mixture was stirred for 1 hour by cooling then it was stirred for 10-15 hours at room temperature. The precipitated product was filtered off and washed with ice-cool water (3x20 ml). The title product was dried in vacuum at 400C. Yield: 4.5 g (90%). Melting point: 150-180 °C, protracted.

Claims

1. A process for the preparation of rosuvastatin of formula I
Figure imgf000020_0001
which comprises one of the following processes c.) reacting a compound of formula II,
Figure imgf000020_0002
-wherein R represents C1-4 alkyl except tert-butyl group- by alkalic hydrolysis to give a compound of formula III
Figure imgf000021_0001
thereafter reacting with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or
b.) reacting a compound of formula III
Figure imgf000021_0002
with an organic or inorganic base to form a salt, eliminating the acetonide group and reacting with calcium-chloride in a base; or
c.) reacting a salt of a compound of formula III
Figure imgf000022_0001
-formed with an organic or inorganic base- by eliminating the acetonide group and reacting with calcium-chloride in a base.
2. A process according to claim 1, wherein the salt formation is in a hydrous or anhydrous, neutral organic solvent.
3. A process according to claims 1-2, wherein the neutral organic solvent is acetonitrile , ethyl-acetate or ethanol.
4. A process according to claims 1-3, wherein the salt formation is carried out with methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine, benzylamine, L(-)-
α-methyl-benzylamine or N-methyl-D-glucosamine.
5. A process according to claims 1-4, wherein the salt formation is carried out preferably with diethanolamine, L-lysine or magnesium sulfate.
6. A process according to claims 1-5, wherein the elimination of the acetonide group is carried out in a neutral solvent in the presence of an acid.
7. A process according to claims 1-6., wherein the neutral solvent is tetrahydrofuran.
8. A compound of formula III
Figure imgf000023_0001
and its salts formed by organic or inorganic base.
9. A salt of a compound of formula III according to claim 8, wherein the salt is formed by methylamine, diethanolamine, ethanolamine, magnesium sulfate, L-lysine,
benzylamine, L(-)-α-methyl-benzylamine or N-methyl-D-glucosamine.
10. (6- {(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-6-methyl- pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid-diethanolamine salt.
11. (6- {(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methylamine)-6-methyl- pyrimidin-5-yl]-vinyl}-(4R,6S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid-L-lysine salt.
12. (6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methylamine)-6-methyl- pyrimidin-5-yl]-vinyl}-(4R56S)-2,2-dimethyl-[l,3]dioxan-4-yl)-acetic acid-magnesium salt.
PCT/HU2006/000049 2005-05-26 2006-05-26 Process for the preparation of rosuvastatin Ceased WO2006126035A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MEP-2010-158A ME01781B (en) 2005-05-26 2006-05-26 Process for the preparation of rosuvastatin
HR20100290T HRP20100290T1 (en) 2005-05-26 2006-05-26 Process for the preparation of rosuvastatin and intermediates
PL06744403T PL1902036T3 (en) 2005-05-26 2006-05-26 Process for the preparation of rosuvastatin and intermediates
RSP-2010/0158A RS51205B (en) 2005-05-26 2006-05-26 PROCEDURE FOR OBTAINING ROSUVASTATIN AND ITS INTERMEDIATES
DK06744403.4T DK1902036T3 (en) 2005-05-26 2006-05-26 Process for the preparation of rosuvastatin and intermediates
AT06744403T ATE461924T1 (en) 2005-05-26 2006-05-26 METHOD FOR PRODUCING ROSUVASTATIN AND INTERMEDIATE
EP06744403A EP1902036B1 (en) 2005-05-26 2006-05-26 Process for the preparation of rosuvastatin and intermediates
DE602006013136T DE602006013136D1 (en) 2005-05-26 2006-05-26 ERMEDIATE
EA200702579A EA013304B1 (en) 2005-05-26 2006-05-26 Process for the preparation of rosuvastatin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP0500537 2005-05-26
HU0500537A HU227120B1 (en) 2005-05-26 2005-05-26 Process for the production of the calcium salt of rosuvastatin via new intermediates

Publications (2)

Publication Number Publication Date
WO2006126035A2 true WO2006126035A2 (en) 2006-11-30
WO2006126035A3 WO2006126035A3 (en) 2007-06-14

Family

ID=89986052

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2006/000049 Ceased WO2006126035A2 (en) 2005-05-26 2006-05-26 Process for the preparation of rosuvastatin

Country Status (13)

Country Link
EP (1) EP1902036B1 (en)
AT (1) ATE461924T1 (en)
DE (1) DE602006013136D1 (en)
DK (1) DK1902036T3 (en)
EA (1) EA013304B1 (en)
ES (1) ES2342788T3 (en)
HR (1) HRP20100290T1 (en)
HU (1) HU227120B1 (en)
ME (1) ME01781B (en)
PL (1) PL1902036T3 (en)
RS (1) RS51205B (en)
SI (1) SI1902036T1 (en)
WO (1) WO2006126035A2 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036286A1 (en) * 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
WO2009157014A3 (en) * 2008-01-30 2010-07-22 Cadila Healthcare Limited A process for preparing hmg-coa reductase inhibitors and intermediates
WO2010082072A1 (en) 2009-01-15 2010-07-22 Egis Gyógyszergyár Process for the preparation of rosuvastatin salts
WO2011104725A2 (en) 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
CN102358747A (en) * 2011-08-30 2012-02-22 浙江宏元药业有限公司 Rosuvastatin calcium intermediate and method for preparing rosuvastatin calcium intermediate and rosuvastatin calcium
WO2012038785A1 (en) * 2010-09-21 2012-03-29 Biocon Limited Polymorphs of rosuvastatin acetonide calcium ((3r,5s,6e)-7-[4-(4- fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimn)in-5- yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl) acetic acid calcium salt
WO2012046193A1 (en) * 2010-10-06 2012-04-12 Laboratorios Senosiain S.A. De C.V. New salt of a pyrimidin derivative
WO2012073256A1 (en) * 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
CN102796036A (en) * 2012-09-12 2012-11-28 江苏阿尔法药业有限公司 Preparation method of atorvastatin calcium

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
GB0011163D0 (en) * 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008036286A1 (en) * 2006-09-18 2008-03-27 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia
WO2009157014A3 (en) * 2008-01-30 2010-07-22 Cadila Healthcare Limited A process for preparing hmg-coa reductase inhibitors and intermediates
US20110245285A1 (en) * 2008-09-09 2011-10-06 Biocon Limited Process for preparation of rosuvastatin acetonide calcium
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
WO2010082072A1 (en) 2009-01-15 2010-07-22 Egis Gyógyszergyár Process for the preparation of rosuvastatin salts
WO2011104725A2 (en) 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
WO2012038785A1 (en) * 2010-09-21 2012-03-29 Biocon Limited Polymorphs of rosuvastatin acetonide calcium ((3r,5s,6e)-7-[4-(4- fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimn)in-5- yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl) acetic acid calcium salt
WO2012046193A1 (en) * 2010-10-06 2012-04-12 Laboratorios Senosiain S.A. De C.V. New salt of a pyrimidin derivative
ES2409805R1 (en) * 2010-10-06 2013-07-15 Senosiain S A De C V Lab NEW SALT OF A PYRIMIDINE DERIVATIVE
US8846708B2 (en) 2010-10-06 2014-09-30 Laboratorios Senosiain S.A. De C.V. Salt of a pyrimidin derivative
WO2012073256A1 (en) * 2010-11-29 2012-06-07 Cadila Healthcare Limited Salts of rosuvastatin
CN102358747A (en) * 2011-08-30 2012-02-22 浙江宏元药业有限公司 Rosuvastatin calcium intermediate and method for preparing rosuvastatin calcium intermediate and rosuvastatin calcium
CN102796036A (en) * 2012-09-12 2012-11-28 江苏阿尔法药业有限公司 Preparation method of atorvastatin calcium
CN102796036B (en) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 Preparation method of atorvastatin calcium

Also Published As

Publication number Publication date
EA200702579A1 (en) 2008-04-28
WO2006126035A3 (en) 2007-06-14
EA013304B1 (en) 2010-04-30
ATE461924T1 (en) 2010-04-15
DE602006013136D1 (en) 2010-05-06
PL1902036T3 (en) 2010-08-31
ME01781B (en) 2010-12-31
EP1902036B1 (en) 2010-03-24
HUP0500537A3 (en) 2008-04-28
HRP20100290T1 (en) 2010-06-30
SI1902036T1 (en) 2010-05-31
HU0500537D0 (en) 2005-08-29
RS51205B (en) 2010-12-31
HU227120B1 (en) 2010-07-28
DK1902036T3 (en) 2010-06-28
HUP0500537A2 (en) 2007-05-02
EP1902036A2 (en) 2008-03-26
ES2342788T3 (en) 2010-07-14

Similar Documents

Publication Publication Date Title
EP2024341B1 (en) Novel process for statins and its pharmaceutically acceptable salts thereof
US8487105B2 (en) Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
JP5146965B2 (en) Method for preparing amorphous rosuvastatin calcium free of impurities
CN102282136B (en) Process for the preparation of rosuvastatin
NZ513261A (en) Process for the production of tert-butyl (E)-(6-[2-[4- (4-fluorophenyl)-6-isopropyl-2- [methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl](4R,6S)- 2,2-dimethyl[1,3]dioxan-4-yl)acetate
US6172227B1 (en) 4,5-diaminopyrimidine derivatives and a method for the preparation thereof
WO2005054207A1 (en) Process for the preparation of pyrimidine derivatives
JP2007509119A (en) Rosuvastatin (E) -7-'4- (4-fluorophenyl) -6-isopropyl-2-'methyl (methylsulfonyl) amino! Pyrimidin-5-yl! Calcium salt of (3R, 5S) -3,5-dihydroxyhept-6-enoic acid and method for producing crystalline intermediates thereof
EP1902036B1 (en) Process for the preparation of rosuvastatin and intermediates
US8394956B2 (en) Process for preparing pyrimidine propenaldehyde
EP2439198A2 (en) Novel method for preparing rosuvastatin, intermediate compounds useful for preparing same, and method for preparing same
WO2008038132A1 (en) Crystalline diamine salts of rosuvastatin
JP2009530232A (en) Method for producing rosuvastatin potassium
WO2010035284A2 (en) An improved process for the preparation of rosuvastatin calcium
JP2013543884A (en) Manufacturing method for high-purity pharmaceutical intermediates
EP2646419B1 (en) Method for preparing rosuvastatin salts
EP2086946A2 (en) Rosuvastatin dehydroabietylamine salt
WO2015131405A1 (en) Intermediate compound for preparing rosuvastatin calcium and method for preparing rosuvastatin calcium therefrom
JP2013529223A (en) Process for producing intermediate of pitavastatin or a salt thereof
JP6034888B2 (en) Novel statin intermediate and method for producing pitavastatin, rosuvastatin, cerivastatin and fluvastatin using the same
HK1187051A (en) Method for preparing rosuvastatin salts

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006744403

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200702579

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWP Wipo information: published in national office

Ref document number: 2006744403

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P-2010/0158

Country of ref document: RS